In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: Results of the CANWARD 2007-2009 study

Diagnostic Microbiology and Infectious Disease

Volumn 69, Issue 3, 2011, Pages 342-347

  Karlowsky, James A ^a,b   Adam, Heather J ^a,b   Poutanen, Susan M ^c   Hoban, Daryl J ^a,b   Zhanel, George G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Diagnostic Services of Manitoba Inc   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Dalbavancin; Telavancin; Vancomycin

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CANADA; DRUG ACTIVITY; DRUG POTENCY; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CANADA; HOSPITALS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TEICOPLANIN; VANCOMYCIN;

EID: 79951865866     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.10.031     Document Type: Article

References (26)

1. Biedenbach D.J., Bell J.M., Sader H.S., Turnidge J.D., Jones R.N. Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates. Antimicrob. Agents Chemother. 2009, 53:1260-1263.
2. Biedenbach D.J., Ross J.E., Fritsche T.R., Sader H.S., Jones R.N. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J. Clin. Microbiol. 2007, 45:998-1004.
3. Chen A.Y., Zervos M.J., Vazquez J.A. Dalbavancin: a novel antimicrobial. Int. J. Clinic. Practice. 2007, 61:853-863.
4. Christianson S., Golding G.R., Campbell J., the Canadian Nosocomial Infection Surveillance Program,, Mulvey M.R. Comparative genomics of Canadian epidemic lineages of methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 2007, 45:1904-1911.
5. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard-seventh edition, M7-A7 2006, CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 20th information supplement (M100-S20) 2010, CLSI, Wayne, PA.
7. Crandon J., Nicolau D.P. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens. Future Microbiol. 2008, 3:251-263.
8. Draghi D.C., Benton B.M., Krause K.M., Thornsberry C., Pillar C., Sahm D.F. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 2008, 52:2383-2388.
9. Eliopoulos G.M. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. J. Infect. 2009, 59:S17-S24.
10. Goldstein B.P., Draghi D.C., Sheehan D.J., Hogan P., Sahm D.F. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob. Agents Chemother.. 2007, 51:1150-1154.
11. Gales A.C., Sader H.S., Jones R.N. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect. 2005, 11:95-100.
12. Golding G., Campbell J., Spreitzer D., Veyhl J., Surynicz K., Simor A., Mulvey M.R., Canadian Nosocomial Infection Surveillance Program A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field electrophoresis epidemic type using spa typing. Can. J. Infect. Dis. Med. Microbiol. 2008, 19:273-281.
13. Hoban D.J., Zhanel G.G. Introduction to the CANWARD study, 2007-2009. Diagn. Microbiol. Infect. Dis. 2011, 69:289-290.
14. Jones R.N., Stilwell M.G., Sader H.S., Fritsche T.R., Goldstein B.P. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microb. Infect. Dis. 2006, 54:149-153.
15. Leuthner K.D., Cheung C.M., Rybak M.J. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 2006, 2006(58):338-343.
16. Mendes R.E., Moet G.J., Janechek M.J., Jones R.N. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob. Agents Chemother.. 2010, 54:2704-2706.
17. Mulvey M.R., Chiu L., Ismail J., Louie L., Murphy C., Chang N., Alfa M. Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis. J. Clin. Microbiol. 2001, 39:3481-3485. the Canadian Committee for the Standardization of Molecular Methods.
18. Mulvey M.R., MacDougall L., Cholin B., Horsman G., Fidyk M., Woods S. Community-associated methicillin-resistant Staphylococcus aureus. Canada. Emerg. Infect. Dis. 2005, 11:844-850. the Saskatchewan CA-MRSA Study Group.
19. Oliveira D.C., de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2002, 46:2155-2161.
20. Saravolatz L.D., Stein G.E., Johnson L.B. Telavancin: a novel lipoglycopeptide. Clin. Infect. Dis. 2009, 49:1908-1914.
21. Streit J.M., Sader H.S., Fritsche T.R., Jones R.N. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn. Microbiol. Infect. Dis. 2005, 53:307-310.
22. Vibativ Vibativ (telavancin) for injection, package insert 2009, Theravance Inc., San Francisco, CA.
23. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C. October 2008, 2008:25-28.
24. Zhanel G.G., Adam H.J., Low D.E., Blondeau J., DeCorby M., Karlowsky J., Weshnoweski B., Vashisht R., Wierzbowski A., Hoban D.J. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis. 2011, 69:291-306. the Canadian Antimicrobial Resistance Alliance.
25. Zhanel G.G., DeCorby M., Nichol K.A., et al. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn. Microb. Infect. Dis. 2008, 62:67-80.
26. Zhanel G.G., Calic D., Schweizer F., Zelenitsky S., Adam H., Lagacé-Wiens P.R.S., Rubinstein E., Gin A.S., Hoban D.J., Karlowsky J.A. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010, 70:859-886.